Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

The KP.3.1.1 variant, part of the Omicron family, has been the strain ... Everyone 6 months and older 2024–2025 Pfizer-BioNTech COVID-19 Vaccine: Everyone 6 months and older 2024–2025 Novavax ...

Este artículo estará disponible en español en El Tiempo Latino. Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall ...

On July 3, 2024, BioNTech and Pfizer’s Omicron JN.1-adapted COVID-19 vaccine was approved by the European Commission (“EC”). Shortly following approval, the updated vaccines were made ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...